Skip to NavigationSkip to content

Mylan issues recall for anxiety drug Xanax over contamination fears

Published on 29/10/19 at 10:58am
Image credit: Dean812, https://www.flickr.com/photos/deanslife/1269477821

Mylan has announced it has issued a recall of its anxiety therapy Xanax (alprazolam) over suspicions the drug could be contaminated with a “foreign substance” and pose a risk to patients.

The alert was made known via the FDA website and concerns the 0.5mg tablet formulation of the drug, made available throughout July and August this year in bottles of 500.

"Clinical impact from the foreign material, if present, is expected to be rare, but the remote risk of infection to a patient cannot be ruled out," said Mylan in the notice. "To date, Mylan has not received any adverse events related to this batch."

The drugmaker contacted wholesalers and retailers with instructions to return the affected product; consumers were also contacted in turn with similar instructions. Xanax is typically used for the management of anxiety disorder, and can provide relief for panic disorder.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches